OakChart

Aktis Oncology Inc

AKTSHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

17.04-0.41 (-2.35%)
2026-11-12 03:36 CET
Market cap
947.76 USD m
Revenue, TTM
3.38 USD m
Net income, TTM
-24.14 USD m
Free cash flow, TTM
-21.85 USD m
EPS diluted, TTM
-0.44
P/E
-
Compare

Price

AKTS against its 20, 50 and 200-day averages
2050200beat
15.0020.0025.0030.0035.001.4M2.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AKTSclose 17.0420-day 15.9650-day 18.96200-day 20.8117.0452w high52w low

50.2% under the 52-week high of 34.19 on 30 Jun 2026. 52-week low 13.96 on 2 Nov 2026. Last 15 sessions, 28.0% high to low

Volume 0.45× normal · the line is the 50-bar volume average

Profile

AKTS
52-week range, 15% of the way up
13.9634.19

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

IndexRUT
Employees79
IPOJan 09, 2026
ATR, 14d1.09
Rel volume0.45
Short float14.05%
Insider own43.37%
Inst own43.25%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap947.76M
Enterprise Value441.68M
Income-
Sales-
Book/sh8.76
Cash/sh9.30
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees79
IPOJan 09, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.94
P/C1.83
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio16.33
Current Ratio16.33
Debt/Eq0.02
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-
EPS next Y-2.25
EPS next Q-0.46
EPS this Y97.72%
EPS next Y-26.15%
EPS next 5Y68.48%
EPS past 3/5Y-47.94% -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-55.52%
Sales Q/Q133.86%
EarningsAug 13 AMC
EPS/Sales Surpr.-0.19% 25.44%

Ownership

Insider Own43.37%
Insider Trans-0.50%
Inst Own43.25%
Inst Trans-0.74%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.76%
SMA50-10.11%
SMA200-18.13%
Trades-

Technical

Shs Outstand53.45M
Shs Float31.50M
Short Float14.05%
Short Ratio11.48
Short Interest4.43M
52W High34.19 -50.16%
52W Low13.96 22.06%
Volatility7.11% 6.86%
ATR (14)1.09
RSI (14)50.89
Beta-
Rel Volume0.45
Avg Volume385.54K
Volume173,983

Performance

Perf Week12.11%
Perf Month2.40%
Perf Quarter-28.37%
Perf Half Y-12.75%
Perf YTD-36.89%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price36.00
Prev Close17.45
Price17.04
Change %-2.35%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Sep 09, 2026InitiatedOOppenheimerOutperform$40+134.7%
Aug 19, 2026InitiatedWWedbushOutperform$35+105.4%
Aug 19, 2026InitiatedBBMO Capital MarketsOutperform$37+117.1%
Jun 16, 2026InitiatedRRaymond JamesStrong Buy$40+134.7%
Apr 29, 2026InitiatedWWilliam BlairOutperform
Mar 09, 2026InitiatedHH.C. WainwrightBuy$30+76.1%
Feb 03, 2026InitiatedTTD CowenBuy
Feb 03, 2026InitiatedLLeerink PartnersOutperform$31+81.9%
Feb 03, 2026InitiatedJJP MorganOverweight$30+76.1%
Feb 03, 2026InitiatedBBofA SecuritiesBuy$34+99.5%

Peers

Mkt cap
TickerCompanyMkt cap
TLXTelix Pharmaceuticals Ltd ADR3.31B
CATXPerspective Therapeutics Inc99.65M
DRTSAlpha Tau Medical Ltd1.30B
LNTHLantheus Holdings Inc6.64B
NVSNovartis AG ADR293.47B
BCAXBicara Therapeutics Inc699.06M
BMYBristol-Myers Squibb Co128.59B
RADXRadiopharm Theranostics Ltd ADR12.87M
LLYLilly(Eli) & Co1352.12B
AZNAstrazeneca plc287.66B

Insider trading

latest 14 of 21
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Czibere AkosChief Medical OfficerSep 23 '26Option Exercise4.9512,50061,87512,500Sep 24 04:05 PM
Czibere AkosChief Medical OfficerSep 23 '26Sale20.6912,500258,6210Sep 24 04:05 PM
Akos CzibereOfficerSep 23 '26Proposed Sale22.1125,000552,750Sep 23 04:20 PM
Herrmann KenDirectorJul 20 '26Option Exercise0.594,8562,8594,856Jul 21 08:50 PM
Herrmann KenDirectorJul 20 '26Sale24.564,856119,2740Jul 21 08:50 PM
Herrmann KenDirectorJul 17 '26Option Exercise0.083,0652453,065Jul 20 05:34 PM
Herrmann KenDirectorJul 17 '26Sale25.213,06577,2590Jul 20 05:34 PM
KEN HERRMANNDirectorJul 20 '26Proposed Sale24.564,856119,275Jul 20 04:51 PM
KEN HERRMANNDirectorJul 17 '26Proposed Sale25.213,06577,259Jul 17 05:26 PM
Ron-Bigger ShulamitChief Operating OfficerJul 08 '26Option Exercise3.6650,000183,00050,000Jul 10 06:11 AM
Ron-Bigger ShulamitChief Operating OfficerJul 08 '26Sale27.7550,0001,387,5580Jul 10 06:11 AM
Czibere AkosChief Medical OfficerJul 08 '26Option Exercise4.9550,000247,50050,000Jul 10 06:10 AM
Czibere AkosChief Medical OfficerJul 08 '26Sale27.7750,0001,388,7010Jul 10 06:10 AM
AKOS CZIBEREOfficerJul 08 '26Proposed Sale27.7750,0001,388,700Jul 08 04:28 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
YALLTruth Social God Bless America ETFAUM: 77.70M
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B

News

latest 14 of 50
  • Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 (GlobeNewswire)
  • Aktis Oncology to Present at Upcoming September Investor Conferences (GlobeNewswire)
  • Aktis: Q2 Earnings Snapshot (Associated Press)
  • Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 (GlobeNewswire)
  • Aktis Oncology to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
  • Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors (GlobeNewswire) +6.38%
  • Aktis: Q1 Earnings Snapshot (Associated Press) +7.99%
  • Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 (GlobeNewswire)
  • Aktis Oncology to Present at the BofA Securities Health Care Conference (GlobeNewswire)
  • Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (GlobeNewswire)
  • Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +7.32%
  • Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors (GlobeNewswire)
  • Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results (GlobeNewswire) +8.89% +8.16%
  • Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference (MarketBeat)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.432-0.431-0.4323.382.707
2026Q12026-05-11-0.379-0.362-0.3323.231.935
2025Q42026-02-25-18.190-21.593-0.2841.763.283
2025Q32025-12-03-60.170--1.9104.63--
2026Q3---0.460--4.029
2026Q4---0.493--5.899
2027Q1---0.584--1.716
2027Q2---0.605--1.696
2027Q3---0.638--1.666
2027Q4---0.674--1.676
2028Q1---0.851--2.883
2028Q2---0.866--2.863
2028Q3---0.861--2.853
2028Q4---0.855--2.863
2029Q1---0.962--2.721
2029Q2---0.989--2.711

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-78.340-55.160-78.3406.377.27
2026FY--1.783--15.35
2027FY--2.249--13.67
2028FY--2.452--9.82
2029FY--3.235--7.93
2030FY--2.743--96.28

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-288104.020.0015.00
2026Q3S2026-10-098314.020.0015.00
2026Q3S2026-09-298223.830.0015.00
2026Q3S2026-09-098213.890.0015.00
2026Q3S2026-09-049213.740.0015.00
2026Q3S2026-08-188213.870.0015.00
2026Q3S2026-08-157214.070.0015.00
2026Q3S2026-08-147314.070.0015.00
2026Q3S2026-08-137202.210.005.50
2026Q3S2026-08-127112.140.005.50
2026Q3S2026-07-227212.140.005.50
2026Q3S2026-07-137312.140.005.50
2026Q3S2026-07-107302.210.005.50
2026Q3S2026-06-126302.080.005.50

Estimate history

EPS, annual-0.545-0.837-1.193
Period202320242025
EPS, quarterly-0.23-0.281-0.327-0.284-0.332-0.436
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26
Sales, annual01.4876.497
Period202320242025
Sales, quarterly0.9331.4471.6011.873.2273.384
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26
Shares, annual52.52252.52253.40355.319
Period202320242025MRQ
Shares, quarterly52.52253.40355.31953.40355.27655.319
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue3.386.501.490.00
Cost of Goods Sold Incl. D&A0.882.331.571.12
Gross Profit2.504.17-0.09-1.12
Selling, General and Administrative Excl. Other31.4078.8551.9633.67
Research and Development25.2865.1239.3824.80
Other Operating Expense0.000.000.000.00
Operating Income-28.90-74.68-52.05-34.79
Interest Expense0.000.000.000.00
Unusual Expense0.000.000.01-0.80
Net Income Before Taxes-24.14-63.73-43.98-28.64
Income Taxes0.000.000.000.00
Consolidated Net Income-24.14-63.73-43.98-28.64
Net Income From Continuing Operations-24.14-63.73-43.98-28.64
Net Income-24.14-63.73-43.98-28.64
EPS (Recurring)-0.44-1.19-0.84-0.56
EPS (Basic, Before Extraordinaries)-0.44-1.19-0.84-0.55
EPS (Diluted)-0.44-1.19-0.84-0.55
EBITDA-28.02-72.36-50.48-33.67
Non-Operating Income (Expense)4.7510.958.085.35
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense3.225.132.261.48
Gross Margin-64.15-5.92-
Operating Margin--1,149.52-3,500.34-
Net Margin--980.93-2,957.63-
Shares Outstanding55.3253.4052.5252.52
Market Capitalization947.76947.76--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Total Revenue3.383.231.871.601.450.93
Cost of Goods Sold Incl. D&A0.880.650.690.550.480.44
Gross Profit2.502.581.181.050.960.49
Selling, General and Administrative Excl. Other31.4025.2818.5522.0119.1116.13
Research and Development25.2820.0415.8018.6315.8612.16
Other Operating Expense0.000.000.000.000.000.00
Operating Income-28.90-22.71-17.38-20.96-18.14-15.63
Interest Expense0.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-24.14-18.32-15.14-18.07-14.98-12.06
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-24.14-18.32-15.14-18.07-14.98-12.06
Net Income From Continuing Operations-24.14-18.32-15.14-18.07-14.98-12.06
Net Income-24.14-18.32-15.14-18.07-14.98-12.06
EPS (Recurring)-0.44-0.33-0.28-0.33-0.28-0.23
EPS (Basic, Before Extraordinaries)-0.44-0.33-0.28-0.33-0.28-0.23
EPS (Diluted)-0.44-0.33-0.28-0.33-0.28-0.23
EBITDA-28.02-22.05-16.68-20.41-17.66-15.19
Non-Operating Income (Expense)4.754.382.242.893.163.58
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense3.223.021.101.521.241.05
Gross Margin74.0279.8062.8365.5266.5552.73
Operating Margin-853.99-703.63-929.14-1,309.37-1,253.84-1,675.78
Net Margin-713.48-567.86-809.52-1,128.98-1,035.59-1,292.18
Shares Outstanding55.3255.2853.4055.3253.4052.52
Market Capitalization947.76986.99912.51---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments226.79297.1797.86
Short Term Receivables0.000.000.00
Inventories0.000.000.00
Other Current Assets3.523.692.34
Total Current Assets230.31300.85100.20
Net Property, Plant & Equipment27.2520.8720.92
Total Investments and Advances1.151.151.15
Deferred Tax Assets5.125.054.08
Other Assets6.183.310.08
Total Assets270.01331.23126.43
Short Term Debt Incl. Current Port. of LT Debt1.311.301.53
Accounts Payable1.741.920.96
Other Current Liabilities28.1815.613.75
Total Current Liabilities31.2418.826.24
Long Term Debt10.2310.7111.87
Provision for Risks Charges0.000.000.00
Deferred Tax Liabilities5.125.054.08
Other Liabilities36.1651.040.50
Total Liabilities82.7585.6222.69
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value333.41333.41150.05
Common Equity-146.15-87.80-46.31
Total Shareholders Equity187.26245.61103.74
Accumulated Minority Interest0.000.000.00
Total Equity187.26245.61103.74
Total Liabilities & Stockholders Equity270.01331.23126.43
Book Value Per Share-2.74-1.67-0.88
Tangible Book Value Per Share-2.74-1.67-0.88
Full-Time Employees79--
Price to Book Ratio1.94--
Return on Assets-21.20-19.22-
Return on Equity-29.45-25.18-
Return on Invested Capital-32.27-17.16-24.77
Quick Ratio7.3715.9816.07
Current Ratio7.3715.9816.07

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income-24.14-63.73-43.98-28.64
Depreciation0.882.331.571.12
Other Funds (Non Cash)2.190.51-1.81-2.47
Funds from Operations-21.08-60.90-44.22-29.99
Extraordinary Item0.000.000.000.00
Changes in Working Capital0.49-3.2358.98-0.01
Cash from Operating Activities-20.59-64.1314.76-30.00
Capital Expenditures-1.26-9.58-2.86-3.76
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.06
Purchase or Sale of Investments-267.4575.55-187.54-65.12
Purchase of Investments-300.45-193.87-288.40-145.81
Sale Or Maturity of Investments33.00269.42100.8680.69
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-268.7165.96-190.40-68.83
Cash Dividends Paid0.000.000.000.00
Preferred Dividends (Cash Flow)0.00---
Change in Capital Stock0.160.34184.830.00
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock0.160.34184.830.00
Proceedsfrom Stock Options0.000.00184.650.00
Issuance or Reduction of Debt, Net0.000.000.000.00
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.00-1.55-1.550.00
Other Financing Activities Uses0.00-1.55-1.550.00
Cash from Financing Activities0.16-1.21183.280.00
Net Change in Cash-289.140.627.65-98.83
Free Cash Flow-21.85-73.7111.90-33.77
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Cash & Short Term Investments517.32538.48226.79--297.17
Short Term Receivables2.302.200.00--0.00
Inventories0.000.000.00--0.00
Other Current Assets4.923.263.52--3.69
Total Current Assets524.54543.94230.31--300.85
Net Property, Plant & Equipment28.2028.1127.25--20.87
Total Investments and Advances1.151.151.15--1.15
Deferred Tax Assets--5.12--5.05
Other Assets3.713.606.18--3.31
Total Assets557.60576.80270.01--331.23
Short Term Debt Incl. Current Port. of LT Debt1.481.431.31--1.30
Accounts Payable2.531.231.74--1.92
Other Current Liabilities28.1225.2628.18--15.61
Total Current Liabilities32.1327.9131.24--18.82
Long Term Debt9.7610.1510.23--10.71
Provision for Risks Charges0.000.000.00--0.00
Deferred Tax Liabilities--5.12--5.05
Other Liabilities30.8732.6336.16--51.04
Total Liabilities72.7670.6982.75--85.62
Non-Equity Reserves0.000.000.00--0.00
Preferred Stock - Carrying Value0.000.00333.41--333.41
Common Equity484.84506.11-146.15---87.80
Total Shareholders Equity484.84506.11187.26--245.61
Accumulated Minority Interest0.000.000.00--0.00
Total Equity484.84506.11187.26--245.61
Total Liabilities & Stockholders Equity557.60576.80270.01--331.23
Book Value Per Share8.769.16-2.74---1.67
Tangible Book Value Per Share8.769.16-2.74---1.67
Full-Time Employees--79---
Price to Book Ratio1.94-6.54-6.04---
Return on Invested Capital-4.88-3.55-7.67---4.70
Quick Ratio16.3319.497.37--15.98
Current Ratio16.3319.497.37--15.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Net Income-24.14-18.32--18.07-14.98-
Depreciation0.880.65-0.550.48-
Other Funds (Non Cash)2.192.49-0.20-0.62-
Funds from Operations-21.08-15.18--17.32-15.12-
Extraordinary Item0.000.00-0.000.00-
Changes in Working Capital0.49-9.06-1.14-2.36-
Cash from Operating Activities-20.59-24.24--16.18-17.48-
Capital Expenditures-1.26-1.85--1.53-1.89-
Net Assets From Acquisitions0.000.00-0.000.00-
Sale of Fixed Assets and Businesses0.000.00-0.000.00-
Purchase or Sale of Investments-267.4522.39-69.6840.93-
Purchase of Investments-300.450.00-0.00-10.82-
Sale Or Maturity of Investments33.0022.39-69.6851.75-
Other Uses0.000.00-0.000.00-
Other Sources0.000.00-0.000.00-
Cash from Investing Activities-268.7120.54-68.1439.04-
Cash Dividends Paid0.000.00-0.000.00-
Preferred Dividends (Cash Flow)0.000.00-0.000.00-
Change in Capital Stock0.16337.55-0.00-0.47-
Repurchase of Common Pref Stock0.000.00-0.000.00-
Sale of Common Pref Stock0.16337.55-0.00-0.47-
Proceedsfrom Stock Options0.00337.52-0.00-0.52-
Issuance or Reduction of Debt, Net0.000.00-0.000.00-
Change in Long Term Debt0.000.00-0.000.00-
Issuance of Long Term Debt0.000.00-0.000.00-
Reduction of Long Term Debt0.000.00-0.000.00-
Net Financing Active Other Cash Flow0.000.00-0.000.00-
Other Financing Activities Uses0.000.00-0.000.00-
Cash from Financing Activities0.16337.55-0.00-0.47-
Net Change in Cash-289.14333.85-51.9721.09-
Free Cash Flow-21.85-26.10--17.71-19.38-

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.05%4.4M31.5M360.11K
2026-10-1513.69%4.3M31.5M358.91K
2026-09-3014.97%4.7M31.5M392.74K
2026-09-1510.33%3.3M31.5M391.18K
2026-08-3110.08%3.2M31.5M385.01K
2026-08-1410.99%3.4M31.4M360.07K
2026-07-3110.92%3.5M31.8M347.52K
2026-07-1511.77%3.7M31.8M346.52K
2026-06-3010.40%3.3M31.8M308.32K
2026-06-159.17%2.9M31.8M326.15K
2026-05-298.39%2.7M31.8M319.40K
2026-05-157.95%2.5M31.8M326.29K
2026-04-308.79%2.6M29.3M346.98K
2026-04-158.35%2.3M28.1M352.70K
2026-03-318.27%2.3M28.1M423.79K
2026-03-134.02%1.2M29.0M327.33K
2026-02-273.63%1.0M27.6M361.94K
2026-02-133.33%0.9M27.6M422.21K
2026-01-300.70%0.2M28.0M527.58K
2026-01-150.17%0.0M28.0M1.01M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call10.005.709.500.006.6790.000.000.877-0.3310.005
call12.503.007.000.004.9020.000.000.810-0.3320.007
call15.001.205.002.003.9795200.000.730-0.3050.009
call17.500.304.901.244.8946.000.000.630-0.2690.010
call20.000.004.900.405.6371150.000.601-0.3270.010
call22.500.004.900.006.0980.000.000.578-0.3620.011
call25.000.004.900.006.4250.000.000.559-0.3890.011
call30.000.001.150.003.3770.000.000.225-0.1530.008
call35.000.004.900.007.8790.000.000.525-0.4750.011
put10.000.004.900.0010.9420.000.00-0.118-0.3260.005
put12.500.004.900.008.2650.000.00-0.182-0.3290.007
put15.000.004.901.206.14164.000.00-0.270-0.3040.009
put17.500.304.900.004.4520.000.00-0.370-0.2670.010
put20.001.205.504.503.3990.000.00-0.399-0.3250.010
put22.503.007.500.003.5210.000.00-0.421-0.3630.010
put25.005.5010.009.104.0040.000.00-0.438-0.3950.010
put30.0010.5014.500.004.2400.000.00-0.749-0.1770.008
put35.0015.5019.500.004.8150.000.00-0.769-0.1940.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-244Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-23144Filing for proposed sale of securities under Rule 144.SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-07-20144Filing for proposed sale of securities under Rule 144.SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-17144Filing for proposed sale of securities under Rule 144.SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-08144Filing for proposed sale of securities under Rule 144.SEC
2026-07-08144Filing for proposed sale of securities under Rule 144.SEC
2026-05-14SCHEDULE 13GSEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-164Statement of changes in beneficial ownership of securities2026-04-15SEC
2026-04-163Initial statement of beneficial ownership of securities2026-04-15SEC
2026-04-168-KCurrent report2026-04-15SEC
2026-03-318-KCurrent report2026-03-30SEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-01-20SCHEDULE 13DSEC
2026-01-20SCHEDULE 13DSEC
2026-01-15SCHEDULE 13DSEC
2026-01-153Initial statement of beneficial ownership of securities2026-01-12SEC
2026-01-144Statement of changes in beneficial ownership of securities2026-01-12SEC
2026-01-144Statement of changes in beneficial ownership of securities2026-01-12SEC
2026-01-144Statement of changes in beneficial ownership of securities2026-01-12SEC
2026-01-14SCHEDULE 13DSEC
2026-01-124Statement of changes in beneficial ownership of securities2026-01-12SEC
2026-01-124Statement of changes in beneficial ownership of securities2026-01-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900258.62K1
2026-080000
2026-07002.97M4
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-01114.31M600
2025-120000
2025-110000

Institutional holders

Manager% owned
MPM BioImpact LLC8.75%
EcoR1 Capital, LLC8.73%
Blue Owl Capital Holdings LP5.55%
BlackRock, Inc.4.12%
T. Rowe Price Investment Management, Inc.3.71%
WELLINGTON MANAGEMENT GROUP LLP3.56%
RTW INVESTMENTS, LP2.88%
RA CAPITAL MANAGEMENT, L.P.2.38%
Jupiter Topco LLC2.38%
BAKER BROS. ADVISORS LP1.80%

Funds

Fund% owned
VANGUARD HEALTH CARE FUND2.65%
T. Rowe Price Small-Cap Stock Fund, Inc.1.22%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.06%
iShares Russell 2000 ETF0.99%
Eventide Healthcare & Life Sciences Fund0.92%
T. Rowe Price Institutional Small-Cap Stock Fund0.65%
T. Rowe Price Health Sciences Fund, Inc.0.60%
Select Biotechnology Portfolio0.51%
BlackRock Health Sciences Opportunities Portfolio0.48%
Fidelity Small Cap Index Fund0.42%

OakChart. AKTS. Cached 15 minutes.